RET and non-small cell lung carcinoma: In addition to the LIBRETTO-001 trial, the phase 3 LIBRETTO-431 trial (NCT04194944) showed that first-line selpercatinib significantly extended progression-free survival (PFS) in patients with advanced RET fusion-positive NSCLC, compared to platinum-based chemotherapy with or without pembrolizumab (mPFS: 24.8 [17.3–not estimable] vs. 11.2 [8.8–16.8] months; HR: 0.48 [0.33–0.70], p < 0.001 in overall intent-to-treat analysis) [18].